| Miss Mildred Magsanoc, PT | |
|
114 Hayes Mill Rd, Atco, NJ 08004-2457 | |
| (856) 809-7242 | |
| Not Available |
| Full Name | Miss Mildred Magsanoc |
|---|---|
| Gender | Female |
| Speciality | Physical Therapist - Geriatrics |
| Location | 114 Hayes Mill Rd, Atco, New Jersey |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1346443785 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2251G0304X | Physical Therapist - Geriatrics | 40QAOO730900 (New Jersey) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Miss Mildred Magsanoc, PT 26 Brookstone Dr, Sicklerville, NJ 08081-1692 Ph: () - | Miss Mildred Magsanoc, PT 114 Hayes Mill Rd, Atco, NJ 08004-2457 Ph: (856) 809-7242 |
News Archive
Novartis Pharmaceuticals Corporation announced today that results from a Phase II study show Afinitor® (everolimus) tablets is the first medication in a clinical trial to decrease the size of subependymal giant cell astrocytomas (SEGAs), benign brain tumors associated with tuberous sclerosis (TS). In this study of 28 patients presented today at the 46th American Society of Clinical Oncology (ASCO) annual meeting in Chicago, 75% of patients experienced a reduction of 30% or greater in the size of their brain tumors from baseline to six months (p<0.001).
Onyx Pharmaceuticals, Inc. today announced positive top-line results from the Phase 2b 003-A1 study of single-agent carfilzomib, a selective, next generation proteasome inhibitor, in patients with relapsed and refractory multiple myeloma.
An estimated 6,000 women in the U.S. reach menopause every day (about two million annually).The most common menopausal complaints include hot flashes, sleep disturbances, anxiety, poor mood, and physical and mental exhaustion. Hot flashes affect 80 percent of peri- or postmenopausal women, with 30 percent reporting hot flashes severe enough to seriously affect their quality of life.
ZymoGenetics, Inc. presented interim results today from a Phase 2 clinical trial evaluating Interleukin 21 (IL-21) in combination with Nexavar (sorafenib) tablets in patients with metastatic renal cell cancer.
› Verified 6 days ago
Michael John Loftus Jr., MPT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 501 5th St, Suite 1, Atco, NJ 08004 Phone: 856-768-3811 Fax: 856-768-3869 | |
Janet Mitchell, Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 501 5th St Ste 1, Atco, NJ 08004 Phone: 856-768-3811 | |
Peter Yucis, DPT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 2338 Fernwood Ave, Atco, NJ 08004 Phone: 856-952-8372 | |
Ashley Gale Miller, MPT, CSCS Physical Therapist Medicare: Medicare Enrolled Practice Location: 501 5th St, Atco, NJ 08004 Phone: 856-768-3811 Fax: 856-768-3869 | |
Mr. Anthony M Vittese Iii, MPT,CSCS Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 501 5th St, Suite 1, Atco, NJ 08004 Phone: 856-768-3811 | |
Ivy Kalusa, PT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 114 Hayes Mill Rd, Atco, NJ 08004 Phone: 856-753-2000 | |
Andrew Mallon, DPT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 273 Front St, Atco, NJ 08004 Phone: 856-237-4703 |